Balfaxar Purple Book BLA 125776

BLA number
125776
Proprietary names
Balfaxar
Proper names
Prothrombin complex concentrate, human-lans
Applicant
Octapharma Pharmazeutika Produktionsges.m.b.H.
Center
CBER
First observed release
2023-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001BalfaxarProthrombin complex concentrate, human-lans351(a)500IUFor InjectionIntravenousSingle-Dose VialRxLicensed2023-07-21
002BalfaxarProthrombin complex concentrate, human-lans351(a)1000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2023-07-21

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2024-10-01N002Balfaxar351(a)RxOctapharma Pharmazeutika Produktionsges.m.b.H.
2023-08-01N001Balfaxar351(a)RxOctapharma Pharmazeutika Produktionsges.m.b.H.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2024-10-01002Balfaxar351(a)RxLicensed2023-07-21
2023-08-01001Balfaxar351(a)RxLicensed2023-07-21